An Unusual Case of Acquired AGK-BRAF Gene Fusion in Metastatic EGFR-mutant Lung Adenocarcinoma: A Case Report
Abstract This case report describes a 60-year-old male patient initially diagnosed with metastatic lung adenocarcinoma harboring an epidermal growth factor receptor (EGFR) exon 21 L858R mutation who subsequently developed a rare acquired AGK-BRAF fusion during the course of treatment. This case high...
Saved in:
| Published in | Journal of cancer research and practice Vol. 12; no. 1; pp. 20 - 23 |
|---|---|
| Main Authors | , , |
| Format | Journal Article |
| Language | English |
| Published |
India
Wolters Kluwer - Medknow
2025
Medknow Publications and Media Pvt. Ltd |
| Edition | 2 |
| Subjects | |
| Online Access | Get full text |
| ISSN | 2589-0425 2311-3006 2311-3006 |
| DOI | 10.4103/ejcrp.eJCRP-D-24-00023 |
Cover
| Abstract | Abstract
This case report describes a 60-year-old male patient initially diagnosed with metastatic lung adenocarcinoma harboring an epidermal growth factor receptor (EGFR) exon 21 L858R mutation who subsequently developed a rare acquired AGK-BRAF fusion during the course of treatment. This case highlights the complexity of managing EGFR-mutant lung cancer with additional acquired genetic alterations, the potential role of these alterations in treatment resistance, and the importance of comprehensive genomic profiling in guiding personalized treatment strategies. |
|---|---|
| AbstractList | Abstract
This case report describes a 60-year-old male patient initially diagnosed with metastatic lung adenocarcinoma harboring an epidermal growth factor receptor (EGFR) exon 21 L858R mutation who subsequently developed a rare acquired AGK-BRAF fusion during the course of treatment. This case highlights the complexity of managing EGFR-mutant lung cancer with additional acquired genetic alterations, the potential role of these alterations in treatment resistance, and the importance of comprehensive genomic profiling in guiding personalized treatment strategies. This case report describes a 60-year-old male patient initially diagnosed with metastatic lung adenocarcinoma harboring an epidermal growth factor receptor (EGFR) exon 21 L858R mutation who subsequently developed a rare acquired AGK-BRAF fusion during the course of treatment. This case highlights the complexity of managing EGFR-mutant lung cancer with additional acquired genetic alterations, the potential role of these alterations in treatment resistance, and the importance of comprehensive genomic profiling in guiding personalized treatment strategies. This case report describes a 60-year-old male patient initially diagnosed with metastatic lung adenocarcinoma harboring an epidermal growth factor receptor (EGFR) exon 21 L858R mutation who subsequently developed a rare acquired AGK-BRAF fusion during the course of treatment. This case highlights the complexity of managing EGFR-mutant lung cancer with additional acquired genetic alterations, the potential role of these alterations in treatment resistance, and the importance of comprehensive genomic profiling in guiding personalized treatment strategies. Keywords: AGK-BRAF fusion, epidermal growth factor receptor-mutant, nonsmall cell lung cancer |
| Audience | Academic |
| Author | Chang, Ching-Cheng Hsieh, Min-Shu Hsu, Wei-Hsun |
| Author_xml | – sequence: 1 givenname: Ching-Cheng surname: Chang fullname: Chang, Ching-Cheng – sequence: 2 givenname: Min-Shu surname: Hsieh fullname: Hsieh, Min-Shu – sequence: 3 givenname: Wei-Hsun surname: Hsu fullname: Hsu, Wei-Hsun email: whhsu1977@ntu.edu.tw |
| BookMark | eNptkU1PGzEQhq0KpALlL1SWenbw52bDzQ0kfAS1isqlF8vYs8iwawd7V1H_fZeESlRCPoxn9D5zmOcYHcQUAaGvjE4ko-IMnlzeTOBmvv5JLgiXhFLKxSd0xAVjRFBaHYx_Vc8IlVx9RqelPI0RNuNcTuUR6nTE93Eog23x3BbAqcHavQwhg8d6eUu-r_UCLyECXgwlpIhDxHfQ29LbPjh8uVysSTf0NvZ4NcRHrD3E5Gx2IabOnmO9X7uGTcr9F3TY2LbA6Vs9QfeLy1_zK7L6sbye6xVxXCpPrKodqzxnUE8f7Ax45XwlhZQA1sFUubFRomoY9Y0QHuTUMyY5c4xZ-aBAnKBv-72PtgUTYpP6bF0XijO6FrxSNVd8TE0-SI3PQxfceOcmjPP_gGoPuJxKydCYTQ6dzX8Mo-ZVh9npMDsd5sJwaXY6RvD3HtymtodcntthC9l04J9j2n5Ev5NpODU6mjdL5vWcJjXmnyXxF3OhnoI |
| Cites_doi | 10.1056/NEJMoa1713137 10.1038/s43018-021-00195-8 10.1016/j.jtho.2018.12.038 10.1016/j.ccell.2015.08.002 10.1158/1078-0432.CCR-07-2248 10.1200/PO.17.00138 10.1056/NEJMoa1612674 10.1016/S1470-2045(13)70604-1 10.1038/onc.2016.486 10.3389/fonc.2022.863043 10.1200/JCO.2012.44.2806 10.1038/s41591-018-0274-5 10.1002/ijc.29825 10.1016/S1470-2045(14)71173-8 10.1111/pcmr.12388 10.1016/S1470-2045(11)70393-X 10.1200/PO.18.00298 10.1186/s40364-022-00443-8 10.1016/S1470-2045(17)30608-3 10.1200/JCO.2012.46.9270 10.1038/nm.4333 10.1056/NEJMoa0810699 10.1038/s41571-023-00798-3 10.1038/ng.3564 |
| ContentType | Journal Article |
| Copyright | 2025 Journal of Cancer Research and Practice COPYRIGHT 2025 Medknow Publications and Media Pvt. Ltd. |
| Copyright_xml | – notice: 2025 Journal of Cancer Research and Practice – notice: COPYRIGHT 2025 Medknow Publications and Media Pvt. Ltd. |
| DBID | AAYXX CITATION |
| DOI | 10.4103/ejcrp.eJCRP-D-24-00023 |
| DatabaseName | CrossRef |
| DatabaseTitle | CrossRef |
| DatabaseTitleList | CrossRef |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2311-3006 |
| Edition | 2 |
| EndPage | 23 |
| ExternalDocumentID | A832658252 10_4103_ejcrp_eJCRP_D_24_00023 JCRP-12-20 |
| GeographicLocations | Taiwan |
| GeographicLocations_xml | – name: Taiwan |
| GroupedDBID | 0R~ 1P~ 5VS 9RA AAEDW AALRI AAXUO AAYWO ABMAC ACGFS ADEZE ADVLN AEVXI AGHFR AITUG AKRWK ALMA_UNASSIGNED_HOLDINGS AMRAJ EBS EJD FDB GROUPED_DOAJ H13 IAO IHR IPNFZ ITC KQ8 O9- OK1 RIG RMW ROL SSZ TEORI Z5R AAYXX ACVFH ADCNI ADJBI AEUPX AFPUW AIGII AKBMS AKYEP CITATION |
| ID | FETCH-LOGICAL-c245d-a58c16d21e87ba9e26cd64344eeace75c643536f10df33de47d11421c11a4b5e3 |
| IEDL.DBID | W3E |
| ISSN | 2589-0425 2311-3006 |
| IngestDate | Tue Jun 17 21:58:07 EDT 2025 Tue Jun 10 20:59:51 EDT 2025 Tue Jul 01 05:13:47 EDT 2025 Wed May 28 23:01:33 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | nonsmall cell lung cancer epidermal growth factor receptor-mutant AGK-BRAF fusion |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c245d-a58c16d21e87ba9e26cd64344eeace75c643536f10df33de47d11421c11a4b5e3 |
| OpenAccessLink | https://doi.org/10.4103/ejcrp.eJCRP-D-24-00023 |
| PageCount | 4 |
| ParticipantIDs | gale_infotracmisc_A832658252 gale_infotracacademiconefile_A832658252 crossref_primary_10_4103_ejcrp_eJCRP_D_24_00023 wolterskluwer_medknow_10_4103_ejcrp_eJCRP-D-24-00023_20_An_Unusual_Case_of_Acquired |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 20250000 2025-01-00 20250101 |
| PublicationDateYYYYMMDD | 2025-01-01 |
| PublicationDate_xml | – year: 2025 text: 20250000 |
| PublicationDecade | 2020 |
| PublicationPlace | India |
| PublicationPlace_xml | – name: India |
| PublicationTitle | Journal of cancer research and practice |
| PublicationYear | 2025 |
| Publisher | Wolters Kluwer - Medknow Medknow Publications and Media Pvt. Ltd |
| Publisher_xml | – name: Wolters Kluwer - Medknow – name: Medknow Publications and Media Pvt. Ltd |
| References | Peng (R25-20250327) 2015; 28 Yan (R20-20250327) 2022; 12 Chen (R19-20250327) 2023; 11 Zehir (R16-20250327) 2017; 23 Wu (R6-20250327) 2014; 15 Engelman (R13-20250327) 2008; 14 Rosell (R4-20250327) 2012; 13 Yang (R7-20250327) 2015; 16 Soria (R8-20250327) 2018; 378 Travis (R2-20250327) 2013; 31 Mok (R12-20250327) 2017; 376 Vojnic (R18-20250327) 2019; 14 Ross (R14-20250327) 2016; 138 Campbell (R1-20250327) 2016; 48 Leiter (R3-20250327) 2023; 20 Menzies (R22-20250327) 2015; 28 Wu (R9-20250327) 2017; 18 Sheikine (R15-20250327) 2018; 2 Kim (R17-20250327) 2017; 36 Mok (R5-20250327) 2009; 361 Yao (R26-20250327) 2019; 25 Hendifar (R21-20250327) 2021; 5 Passaro (R11-20250327) 2021; 2 Touat (R24-20250327) 2019; 3 Sequist (R10-20250327) 2013; 31 Kim (R23-20250327) 2018; 2 |
| References_xml | – volume: 378 start-page: 113 year: 2018 ident: R8-20250327 article-title: Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1713137 – volume: 2 start-page: 377 year: 2021 ident: R11-20250327 article-title: Overcoming therapy resistance in EGFR-mutant lung cancer publication-title: Nat Cancer doi: 10.1038/s43018-021-00195-8 – volume: 14 start-page: 802 year: 2019 ident: R18-20250327 article-title: Acquired BRAF rearrangements induce secondary resistance to EGFR therapy in EGFR-mutated lung cancers publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2018.12.038 – volume: 28 start-page: 384 year: 2015 ident: R25-20250327 article-title: Inhibition of RAF isoforms and active dimers by LY3009120 leads to anti-tumor activities in RAS or BRAF mutant cancers publication-title: Cancer Cell doi: 10.1016/j.ccell.2015.08.002 – volume: 14 start-page: 2895 year: 2008 ident: R13-20250327 article-title: Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-07-2248 – volume: 2 start-page: 1 year: 2018 ident: R23-20250327 article-title: Significant clinical response to a MEK inhibitor therapy in a patient with metastatic melanoma harboring an RAF1 fusion publication-title: JCO Precis Oncol doi: 10.1200/PO.17.00138 – volume: 376 start-page: 629 year: 2017 ident: R12-20250327 article-title: Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1612674 – volume: 15 start-page: 213 year: 2014 ident: R6-20250327 article-title: Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6):An open-label, randomised phase 3 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(13)70604-1 – volume: 36 start-page: 3334 year: 2017 ident: R17-20250327 article-title: Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition publication-title: Oncogene doi: 10.1038/onc.2016.486 – volume: 12 start-page: 863043 year: 2022 ident: R20-20250327 article-title: BRAF-mutated non-small cell lung cancer:Current treatment status and future perspective publication-title: Front Oncol doi: 10.3389/fonc.2022.863043 – volume: 31 start-page: 3327 year: 2013 ident: R10-20250327 article-title: Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations publication-title: J Clin Oncol doi: 10.1200/JCO.2012.44.2806 – volume: 25 start-page: 284 year: 2019 ident: R26-20250327 article-title: RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling publication-title: Nat Med doi: 10.1038/s41591-018-0274-5 – volume: 138 start-page: 881 year: 2016 ident: R14-20250327 article-title: The distribution of BRAF gene fusions in solid tumors and response to targeted therapy publication-title: Int J Cancer doi: 10.1002/ijc.29825 – volume: 16 start-page: 141 year: 2015 ident: R7-20250327 article-title: Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6):Analysis of overall survival data from two randomised, phase 3 trials publication-title: Lancet Oncol doi: 10.1016/S1470-2045(14)71173-8 – volume: 28 start-page: 607 year: 2015 ident: R22-20250327 article-title: Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion publication-title: Pigment Cell Melanoma Res doi: 10.1111/pcmr.12388 – volume: 13 start-page: 239 year: 2012 ident: R4-20250327 article-title: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC):A multicentre, open-label, randomised phase 3 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(11)70393-X – volume: 5 year: 2021 ident: R21-20250327 article-title: Retrospective case series analysis of RAF family alterations in pancreatic cancer:Real-world outcomes from targeted and standard therapies publication-title: JCO Precis Oncol – volume: 3 start-page: 1 year: 2019 ident: R24-20250327 article-title: Successful targeting of an ATG7-RAF1 gene fusion in anaplastic pleomorphic xanthoastrocytoma with leptomeningeal dissemination publication-title: JCO Precis Oncol doi: 10.1200/PO.18.00298 – volume: 2 year: 2018 ident: R15-20250327 article-title: BRAF in lung cancers:Analysis of patient cases reveals recurrent BRAF mutations, fusions, kinase duplications, and concurrent alterations publication-title: JCO Precis Oncol – volume: 11 start-page: 11 year: 2023 ident: R19-20250327 article-title: The clinical and genomic distinctions of Class1/2/3 BRAF-mutant colorectal cancer and differential prognoses publication-title: Biomark Res doi: 10.1186/s40364-022-00443-8 – volume: 18 start-page: 1454 year: 2017 ident: R9-20250327 article-title: Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050):A randomised, open-label, phase 3 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(17)30608-3 – volume: 31 start-page: 992 year: 2013 ident: R2-20250327 article-title: New pathologic classification of lung cancer:Relevance for clinical practice and clinical trials publication-title: J Clin Oncol doi: 10.1200/JCO.2012.46.9270 – volume: 23 start-page: 703 year: 2017 ident: R16-20250327 article-title: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients publication-title: Nat Med doi: 10.1038/nm.4333 – volume: 361 start-page: 947 year: 2009 ident: R5-20250327 article-title: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma publication-title: N Engl J Med doi: 10.1056/NEJMoa0810699 – volume: 20 start-page: 624 year: 2023 ident: R3-20250327 article-title: The global burden of lung cancer:Current status and future trends publication-title: Nat Rev Clin Oncol doi: 10.1038/s41571-023-00798-3 – volume: 48 start-page: 607 year: 2016 ident: R1-20250327 article-title: Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas publication-title: Nat Genet doi: 10.1038/ng.3564 |
| SSID | ssj0001922474 ssib039765454 |
| Score | 2.2822678 |
| Snippet | Abstract
This case report describes a 60-year-old male patient initially diagnosed with metastatic lung adenocarcinoma harboring an epidermal growth factor... This case report describes a 60-year-old male patient initially diagnosed with metastatic lung adenocarcinoma harboring an epidermal growth factor receptor... |
| SourceID | gale crossref wolterskluwer |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 20 |
| SubjectTerms | Adenocarcinoma Antimitotic agents Antineoplastic agents Case Report Epidermal growth factor Genetic aspects Health aspects Medical colleges |
| Title | An Unusual Case of Acquired AGK-BRAF Gene Fusion in Metastatic EGFR-mutant Lung Adenocarcinoma: A Case Report |
| URI | https://doi.org/10.4103/ejcrp.eJCRP-D-24-00023 |
| Volume | 12 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3di9QwEA96gggifnKr55EHwad4zVe761vc295x54quLt5bSJMUTtn22Nviv-9M2sVdEN98KZSGKfxmMr_JJDMh5E3hxnkefWSuVoKp6DVzUkyYy2QhYSWX6wrzkPNP-flSXVzpq2GhiLUwO_v3imfyJP7w65t38WK6-MxOmVAsdWi5S-6Jgk_Qir_L2dZ-kFohIFB_ciwTIKjUiFloPBkE9tkXCf9D9B4_DV764a8Wt65vf6aT6zv8Uz4mj4bAkZpe00_Indg8Jffnw9b4M7IyDV023W0Hg6ZATbStqfF4zjcGas4u2YeFKSl2maZlhykyet3Qedw4LCm69nR2Vi7YqsNLhelH8ADUgEcColuD-Hbl3lPTi-0j9udkWc6-Tc_ZcJcC80LpwJwee54HweO4qNwkitwHCEaUiuB5Y6E9vGiZ1zwLtZQhqiJglS33nDtV6ShfkIOmbeIhoVUFTqDmOXBbUDHzlYq6Vq7izgVXZ3JETrYI2pu-ZYaFpQZibhPmNmFuT61QNmE-Im8RaItzarN23g2lAfA_7E5lDbgdiJSEFiNytDcS5oLf-_x1T1V21dcU_u3_Ozq3IrOmsYOSLKJp29pulfTyv0h9RR4IvEs4pXOOyMFm3cXXEOBsquOUGIDn5ZfxcbLw39vp9jY |
| linkProvider | Wolters Kluwer Health |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=An+Unusual+Case+of+Acquired+AGK-BRAF+Gene+Fusion+in+Metastatic+EGFR-mutant+Lung+Adenocarcinoma%3A+A+Case+Report&rft.jtitle=Journal+of+cancer+research+and+practice&rft.au=Chang%2C+Ching-Cheng&rft.au=Hsieh%2C+Min-Shu&rft.au=Hsu%2C+Wei-Hsun&rft.date=2025&rft.pub=Wolters+Kluwer+-+Medknow&rft.issn=2589-0425&rft.eissn=2311-3006&rft.volume=12&rft.issue=1&rft.spage=20&rft.epage=23&rft_id=info:doi/10.4103%2Fejcrp.eJCRP-D-24-00023&rft.externalDocID=JCRP-12-20 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2589-0425&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2589-0425&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2589-0425&client=summon |